Pacira BioSciences (PCRX) Convertible Debt (2013 - 2025)

Pacira BioSciences' Convertible Debt history runs 13 years deep, the most recent figure standing at $280.3 million for Q2 2025.

• In Q2 2025, Convertible Debt fell 41.56% year-over-year to $280.3 million; the TTM figure through Jun 2025 stood at $280.3 million (down 41.56% YoY), while the FY2024 annual figure was $279.3 million, down 29.92% from the prior year.
• Convertible Debt was $280.3 million for Q2 2025 at Pacira BioSciences, roughly flat from $279.8 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $479.5 million in Q2 2024 to a low of $278.9 million in Q3 2024.
• Historically, Convertible Debt has averaged $362.0 million across 5 years, with a median of $397.7 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Convertible Debt increased 26.97% in 2022, then slumped 41.56% in 2025.
• A 5-year view of Convertible Debt shows it stood at $339.3 million in 2021, then advanced by 19.31% to $404.8 million in 2022, then fell by 1.53% to $398.6 million in 2023, then retreated by 29.92% to $279.3 million in 2024, then increased by 0.33% to $280.3 million in 2025.
• The last three Convertible Debt figures came in at $280.3 million (Q2 2025), $279.8 million (Q1 2025), and $279.3 million (Q4 2024), per Business Quant data.